Skip to main content
main-content

16-06-2020 | Haematology | Video

EHA25 | CAR T-cell therapy promising for relapsed, refractory large B-cell NHL

Nilanjan Ghosh shares phase 1b trial findings showing high response rates with lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell agent, as second-line therapy in patients with aggressive, relapsed or refractory, large B-cell non-Hodgkin lymphomas who were ineligible for haematopoietic stem cell transplantation (6:46).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits